BLOOD COAGULATION TUBES MARKET ANALYSIS

Blood Coagulation Tubes MarketSize and Trends

According to American Liver Foundation, in 2013, around 30 million people in the U.S.—a whopping 10% of the population—suffered from some form of liver disease. Liver disease is also considered to be the ‘fifth big killer’ in England and Wales, in 2013, as per the WHO-HFA database. Blood coagulation tubes are widely used for diagnosing thrombosis. According to Center for Disease Control and Prevention (CDC), as many as 900,000 people in the U.S. suffer from thrombosis each year. Fibrinogen activity is tested to evaluate bleeding disorders. They are used to diagnose diseases such as disseminated intravascular coagulation. As per Department of Medicine, University of Alabama at Birmingham, in South Asia, especially in India, the fibrinogen levels are usually high, due to high occurrences of coronary heart diseases and higher levels of wound-induced glycoprotein IIb/IIIa that acts as a receptor for fibrinogen. This in turn will result in increased blood coagulation tests in this region. This creates a highly conducive environment for growth of the blood coagulation tubes industry in the region. A report by Journal of Thrombosis and Hemostatis, emphasizes upon the need for controlled and randomized assessments with clinical result measurement to establish that thromboprophylaxis (prevention of thromboembolic disease or obstruction of blood vessels by blood clot) is essential in joint surgery in Asia. Since blood coagulation tests are usually suggested before and after a surgery, growth in number of surgeries is expected to provide major growth traction to the blood coagulation tubes market. As per independent estimates, around 232 million surgeries are performed worldwide each year. Europe and North America are highest revenue contributors to the global blood clotting tubes market. This is mainly attributed to robust healthcare infrastructure and easy access to advanced healthcare facilities in these regions. However, Asia Pacific is expected to emerge as a high growth region in the global blood coagulation market, due to increase in adoption of blood coagulation tests and high prevalence of heart attack and stroke, along with rising incidence of thrombosis and chronic liver diseases in the region.